AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fagron N.V.

Major Shareholding Notification May 5, 2014

3949_mrq_2014-05-05_fbbd884a-71f7-44c1-8628-83dec159f808.pdf

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

Waregem (Belgium) / Rotterdam (Netherlands)1 , 5 May 2014 – Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Arseus NV received a notification on 2 May 2014 from TIAA-CREF Asset Management LLC concerning the acquisition or disposal of voting securities. The shareholding of TIAA-CREF Asset Management LLC crossed the disclosure threshold of 3% and 5% through the acquisition of voting securities.

Based on the denominator of 31,358,358 (total number of voting rights) and the relevant notifications that Arseus received, the shareholder structure as of 5 May 2014 is as follows: Number of shares % of effective voting rights

Number of shares % of effective voting rights
TIAA-CREF Asset Management LLC 1,635,681 5.22%
BNP Paribas Investment Partners SA 1,609,182 5.13%
AXA S.A. 1,413,820 4.51%
Carmignac Gestion 1,396,407 4.45%
Fidelity Management and Research
(FMR LLC)
1,223,000 3.90%
Arseus NV (treasury shares) 881,378 2.81%
Public 23,198,890 73.98%
Total 31,358,358 100.00%

The original notification forms are available at www.arseus.com.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

For more information:

1/2

This press release was sent out by Arseus NV and Arseus BV.

Marieke Palstra Director Investor Relations +31 88 33 11 213 (Office) [email protected]

Arseus profile

Arseus is a R&D scientific company delivering innovative solutions and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into three divisions: Fagron is global market leader in pharmaceutical compounding. Corilus develops and supplies unique integrated ICT solutions with substantial added value to medical specialists and is market leader in Belgium, France and the Netherlands. HL Technology develops and produces innovative precision components and orthopaedic tools for dental and medical professionals. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.

Talk to a Data Expert

Have a question? We'll get back to you promptly.